Last updated: February 12, 2026
Case Overview
Helsinn Healthcare SA filed a patent infringement lawsuit against Mylan Institutional LLC in the District of Delaware. The primary dispute involves Helsinn's patent protections for a formulation of palonosetron—a drug used to prevent chemotherapy-induced nausea and vomiting. Helsinn alleges Mylan's generic versions infringe on its patents, which Helsinn claims are valid and enforceable.
Key Legal Issues
- Patent validity and enforceability
- Infringement under the Hatch-Waxman Act
- Patent term extension and expiration
- Non-obviousness and written description challenges
Timeline and Procedural History
- Filing Date: March 4, 2014
- Initial Claims: Helsinn asserted U.S. Patent No. 8,598,219, granted on November 5, 2013, covering a specific formulation of palonosetron.
- Preliminary Motions: Mylan moved to dismiss and for summary judgment, contesting patent validity.
- Markman Hearing: Interpreted claim terms related to formulation specifics.
- Claim Construction: The court defined the scope of "albumin-binding" and "phosphorylated" features, impacting infringement analysis.
- Summary Judgment: Helsinn moved to exclude Mylan’s invalidity defenses; the court denied parts, ruling some validity challenges could proceed.
- Trial Preparation: Both sides prepared for an infringement/validity trial.
Patent Validity and Enforceability
Helsinn’s patent has a priority date linked to a 2004 application, with a terminal disclaimer maintaining the patent's enforceability through 2028. Helsinn secured a patent term extension until 2028, compensating for regulatory delays.
Mylan challenged patent validity on grounds of obviousness, citing prior art references failing to disclose features claimed by Helsinn. The validity is subject to the USPTO's patent term extension and the impact of the disclaimer.
Infringement Analysis
Helsinn’s formulation patent covers specific concentrations and manufacturing protocols. Mylan’s generic product reportedly uses a similar formulation with phospholipid complex technology. The court examined whether Mylan’s product infringed the patent claims, especially considering the court’s claim interpretation.
Current Status
As of the latest filings, no final judgment issued. The case remains in the litigation stage, with dispositive motions and potential trial proceedings pending. The case's outcome hinges on the court’s assessment of patent validity, infringement, and the impact of the patent term extension.
Legal and Market Implications
- Patent Litigation: The case exemplifies challenges in patent enforcement for drug formulations, especially around the scope of formulation-specific patents.
- Patent Term Adjustment: The extension demonstrates how regulatory delays influence patent expiration and market exclusivity.
- Generic Entry: The case illustrates legal contestations commonly seen before generic market entry for branded pharmaceuticals.
- Strategic Importance: Helsinn's defense reinforces the importance of patent claims covering formulation nuances, while Mylan’s invalidity defenses underscore the reliance on prior art and obviousness arguments.
Key Takeaways
- Helsinn’s patent preserves its market exclusivity until 2028, despite challenges.
- Mylan’s invalidity defenses focus on prior art and claim interpretation, with outcomes susceptible to court’s claim construction.
- The case reflects ongoing tension between patent protections and generic drug competition.
- Patent extensions offered regulatory delay compensation, complicating patent validity challenges.
- Litigation timelines for complex formulation patents extend over several years, influencing market strategies.
FAQs
1. What is the core patent dispute?
It concerns Helsinn’s patent on a specific formulation of palonosetron and whether Mylan’s generic infringes or invalidates that patent.
2. How does patent term extension affect the case?
Extension prolongs Helsinn’s exclusivity period, even amid invalidity or infringement disputes, until 2028.
3. What are common grounds for invalidity claims in biotech patents?
Obviousness based on prior art and lack of written description are primary arguments used against the patent’s validity.
4. How does claim construction influence infringement findings?
Interpreting technical terms determines if Mylan’s formulation falls within Helsinn’s patent scope, affecting infringement rulings.
5. What market implications does this case have?
The case influences potential timing for generic entry and highlights the importance of formulation-specific patent protections.
Citations
[1] Helsinn Healthcare SA v. Mylan Institutional LLC, District of Delaware, Case No. 1:14-cv-00709.
